readthroughSign in
CompanySYRENasdaqWaltham, MA

Spyre Therapeutics, Inc.

Spyre Therapeutics develops extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F for immunology indications, along with combination programs.

424B3Nov 6Latest SEC filing
Nov 3Latest story